• to lessen the potential risk of significant cardiovascular (heart and blood vessel) complications in adults with type 2 diabetes and cardiovascular diseaseIn October 2024, Novo Nordisk released a analyze on scientific journal Mother nature about a novel glucose-sensitive insulin NNC2215 that will decrease the risk of hypoglycemia in animal prod